Financial Performance - The company's operating revenue for Q3 2023 was approximately ¥347 million, representing a year-on-year increase of 58.28%[4] - The net profit attributable to shareholders for Q3 2023 was approximately -¥327 million, with a year-to-date net profit of approximately -¥1.03 billion[4] - Total operating revenue for the first three quarters of 2023 reached RMB 769,470,314.65, a significant increase from RMB 569,635,902.97 in the same period of 2022, representing a growth of approximately 35%[19] - The total operating revenue for Q3 2023 was approximately $769.47 million, an increase from $569.64 million in Q3 2022, representing a growth of 35%[20] - The net profit for Q3 2023 was a loss of approximately $1.03 billion, worsening from a loss of $688.22 million in Q3 2022[20] - The total comprehensive income for Q3 2023 was approximately a loss of $1.04 billion, compared to a loss of $680.11 million in Q3 2022[21] Research and Development - R&D expenses for Q3 2023 totaled approximately ¥318 million, an increase of 49.16% compared to the same period last year[5] - The proportion of R&D expenses to operating revenue was 91.49% for Q3 2023, a decrease of 5.59 percentage points year-on-year[5] - Research and development expenses reached approximately $857.98 million in Q3 2023, compared to $662.54 million in Q3 2022, reflecting a 29.5% increase[20] Assets and Liabilities - The total assets at the end of Q3 2023 were approximately ¥5.51 billion, a decrease of 8.42% from the end of the previous year[5] - As of September 30, 2023, total current assets amounted to RMB 2,235,196,172.88, down from RMB 3,212,137,039.58 at the end of 2022, indicating a decrease of about 30%[16] - The company's total assets decreased to RMB 5,514,357,338.62 from RMB 6,021,189,680.87, reflecting a decline of about 8%[18] - Total liabilities as of September 30, 2023, were RMB 1,558,115,861.03, compared to RMB 1,040,890,051.43 at the end of 2022, indicating an increase of approximately 50%[18] - The company reported a decrease in total equity attributable to shareholders to RMB 3,956,241,477.59 from RMB 4,980,299,629.44, a decline of about 20%[18] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 5,045[11] - The largest shareholder, HKSCC NOMINEES LIMITED, held 34.83% of the shares, totaling approximately 189.57 million shares[11] Cash Flow - The cash flow from operating activities for the first three quarters of 2023 was negative at approximately $1.11 billion, compared to a negative cash flow of $1.08 billion in the same period of 2022[22] - Cash inflow from investment activities in Q3 2023 totaled approximately $846.96 million, an increase from $685.65 million in Q3 2022[23] - The net cash flow from financing activities in Q3 2023 was approximately $511.63 million, a significant decrease from $2.44 billion in Q3 2022[23] - The ending cash and cash equivalents balance for Q3 2023 was approximately $546.09 million, down from $1.97 billion at the end of Q3 2022[23] Earnings Per Share - The company reported a basic and diluted earnings per share of -¥0.61 for Q3 2023[5] - Basic and diluted earnings per share for Q3 2023 were both -1.91 yuan, compared to -1.32 yuan in Q3 2022[21]

Financial Performance - The company's operating revenue for Q3 2023 was approximately CNY 347.04 million, representing a year-on-year increase of 58.28%[6]. - The net profit attributable to shareholders for Q3 2023 was a loss of CNY 327.23 million, with a cumulative loss of CNY 1.03 billion for the year-to-date[6]. - Total operating revenue for the first three quarters of 2023 reached RMB 769,470,314.65, a significant increase of 35% compared to RMB 569,635,902.97 in the same period of 2022[20]. - Net profit for the first three quarters of 2023 was a loss of RMB 1,030,585,859.60, worsening from a loss of RMB 688,219,233.92 in the same period of 2022[21]. - The company experienced a total comprehensive loss of RMB 1,038,494,630.57 in 2023, compared to a loss of RMB 680,108,752.02 in 2022[22]. Research and Development - Research and development expenses totaled CNY 317.52 million in Q3 2023, an increase of 49.16% compared to the same period last year[7]. - The ratio of R&D expenses to operating revenue was 91.49%, a decrease of 5.59 percentage points year-on-year[7]. - The company continues to invest heavily in R&D to support its drug pipeline and clinical trials, leading to increased operational costs[12]. - Research and development expenses increased to RMB 857,977,852.40 in 2023, compared to RMB 662,541,383.59 in 2022, marking a 29.5% rise[21]. Assets and Liabilities - Total assets at the end of Q3 2023 were approximately CNY 5.51 billion, down 8.42% from the end of the previous year[7]. - The equity attributable to shareholders decreased by 20.56% year-on-year, amounting to approximately CNY 3.96 billion[7]. - The company's total assets as of September 30, 2023, amount to ¥5,514,357,338.62, a decrease from ¥6,021,189,680.87 at the end of 2022[19]. - Current assets total ¥2,235,196,172.88, down from ¥3,212,137,039.58 in the previous year[18]. - The total liabilities as of September 30, 2023, are ¥1,558,115,861.03, compared to ¥1,040,890,051.43 in the previous year[19]. Cash Flow - The company reported a net cash flow from operating activities of CNY -1.11 billion for the year-to-date[7]. - Cash flow from operating activities showed a net outflow of RMB 1,114,762,180.68 in 2023, compared to a net outflow of RMB 1,080,292,854.28 in 2022[23]. - Cash inflow from investment activities totaled RMB 846,955,292.55 in 2023, while cash outflow was RMB 1,767,323,954.74, resulting in a net outflow of RMB 920,368,662.19[24]. - The company reported cash and cash equivalents at the end of Q3 2023 amounting to RMB 546,094,957.35, down from RMB 1,967,108,319.61 at the end of Q3 2022[24]. - The company has a total of ¥609,013,239.33 in cash and cash equivalents, down from ¥2,187,326,306.04[18]. Shareholder Information - Total number of common shareholders at the end of the reporting period is 5,045[13]. - HKSCC NOMINEES LIMITED holds 189,566,228 shares, accounting for 34.83% of total shares[14]. Market Strategy - The increase in operating revenue was primarily driven by higher sales of injectable drugs, including TaiTasi and VidiXimab[11]. - The company is focusing on expanding its market presence and developing new products and technologies[16].

Financial Performance - Revenue for the six months ended June 30, 2023, was RMB 419,073 thousand, representing an increase of 20.1% compared to RMB 348,779 thousand for the same period in 2022[8]. - Gross profit for the first half of 2023 was RMB 316,418 thousand, up from RMB 181,274 thousand in the same period of 2022, indicating a significant improvement in profitability[8]. - The company reported a pre-tax loss of RMB 703,362 thousand for the first half of 2023, compared to a loss of RMB 489,126 thousand in the same period of 2022[8]. - The net loss for the period was RMB 703,362 thousand, compared to a net loss of RMB 489,126 thousand in the previous year, indicating a 43.8% increase in losses[104]. - The company reported a basic loss per share of RMB 1.30 for the period, compared to RMB 0.96 in the same period last year[104]. - The company's total comprehensive loss for the period was RMB 709,024 thousand, compared to a loss of RMB 486,630 thousand in the previous year[108]. Assets and Liabilities - Total assets as of June 30, 2023, amounted to RMB 5,831,113 thousand, a decrease from RMB 6,021,191 thousand as of December 31, 2022[8]. - Total liabilities as of June 30, 2023, were RMB 1,535,961 thousand, an increase from RMB 1,040,891 thousand as of December 31, 2022[8]. - The total equity as of June 30, 2023, was RMB 4,295,152 thousand, down from RMB 4,980,300 thousand as of December 31, 2022[8]. - The company's total current assets decreased to RMB 1,264,418,000 as of June 30, 2023, from RMB 2,187,942,000 at the end of 2022[133]. - The company's cash and cash equivalents decreased to RMB 1,119,661 thousand as of June 30, 2023, down from RMB 2,069,180 thousand at the end of 2022[133]. Research and Development - Research and development expenses increased to RMB 540,453 thousand in the first half of 2023, compared to RMB 449,672 thousand in the same period of 2022, reflecting the company's commitment to innovation[8]. - The company is conducting late-stage clinical trials for its proprietary drug, RC18 (brand name: Tai'ai®), targeting eight autoimmune diseases[12]. - The company has over ten drug candidates in its pipeline, with seven in clinical development targeting more than twenty indications[9]. - The company is focusing on the development of its lead antibody-drug conjugate (ADC), RC48, for treating HER2-expressing solid tumors, with multiple late-stage clinical trials ongoing in China[22]. Market and Product Development - The company aims to become a leading player in the global biopharmaceutical industry, focusing on innovative biologics for unmet medical needs[9]. - The commercialization team for autoimmune products has gained access to over 600 hospitals as of June 30, 2023, following the inclusion of Taitasip in the national medical insurance catalog[35]. - Revenue from the Chinese market was RMB 416,118 thousand, up 26.5% from RMB 328,668 thousand in 2022[123]. - The company plans to launch two new products by the end of 2023, targeting a market expansion of 15% in the oncology sector[173]. Shareholder and Equity Structure - As of June 30, 2023, the company’s total shares outstanding are 544,263,003, including 354,681,764 A-shares and 189,581,239 H-shares[2]. - Major shareholders include RongChang Holding Group LTD., which holds approximately 53.20% of A shares and 12.79% of H shares, reflecting significant control over the company[66]. - The company has granted restricted shares under the 2022 A-share incentive plan to several executives, indicating a commitment to align management interests with shareholder value[64]. - The ownership structure suggests potential stability in management decisions, as major shareholders are also involved in the company's strategic direction[63]. Financial Management and Governance - The independent auditor, Ernst & Young, reviewed the interim financial information and found it compliant with applicable accounting standards and regulations[97]. - The company has adopted the corporate governance code and has complied with all applicable code provisions during the reporting period[95]. - The company confirmed that all directors and supervisors complied with the standard code of conduct for securities trading during the reporting period[96]. - The company did not declare or pay any dividends for the six months ended June 30, 2023, consistent with the previous year[128]. Future Outlook - The company plans to utilize all remaining unutilized proceeds by December 31, 2023, based on the best estimates of future market conditions[54]. - The company has set a revenue guidance of RMB 1 billion for the full year 2023, indicating a growth target of 20%[173]. - The company is exploring potential mergers and acquisitions to enhance its product portfolio and market reach[173]. - The company anticipates a positive outlook for the next fiscal year, driven by strong user engagement and innovative product offerings[81].

[Supplemental Announcement to the 2022 Annual Report](index=1&type=section&id=Supplemental%20Announcement%20to%20the%202022%20Annual%20Report) This announcement provides supplementary information to RemeGen Co., Ltd.'s 2022 annual report, detailing awards granted under H-share and A-share schemes and confirming the unchanged status of other annual report content [Details of Awards Granted Under H-share Scheme](index=2&type=section&id=Details%20of%20Awards%20Granted%20Under%20H-share%20Scheme) This section details awards granted under the H-share scheme to directors, the five highest-paid individuals, and other employees, including grant quantities, purchase prices, vesting, and forfeiture Overview of H-share Scheme Awards (As of December 31, 2022) | Grantee Category | Grantee Name | Granted Quantity (Shares) | Purchase Price (HKD) | Vested During Reporting Period (Shares) | Forfeited During Reporting Period (Shares) | Remaining as of Dec 31, 2022 (Shares) | | :--------------- | :----------- | :------------------------ | :------------------- | :-------------------------------------- | :-------------------------------------- | :------------------------------------ | | Executive Director | Fang Jianmin | 1,500,000 | 27.06 | 0 | 0 | 1,500,000 | | Executive Director | He Ruyi | 1,600,000 | 16.91 | 0 | 0 | 1,600,000 | | Five Highest-Paid Individuals | Subtotal | 500,000 | - | 137,500 | 212,500 | 150,000 | | Other Employees | Subtotal | 1,788,380 | - | 197,500 | 228,750 | 1,362,130 | - The exercise period for all H-share awards is **eight years**[2](index=2&type=chunk) [Details of Awards Granted Under A-share Scheme](index=3&type=section&id=Details%20of%20Awards%20Granted%20Under%20A-share%20Scheme) This section provides specific information on awards granted under the A-share scheme to directors, senior management, major shareholders and their associates, and other employees, including grant quantities, grant prices, and vesting periods Overview of A-share Scheme Awards (As of December 31, 2022) | Grantee Category | Grantee Name | Granted Quantity (Shares) | Grant Price (RMB) | Average Closing Price Immediately Prior to Grant Date (RMB) | Remaining as of Dec 31, 2022 (Shares) | | :--------------- | :----------- | :------------------------ | :---------------- | :---------------------------------------------------------- | :------------------------------------ | | Executive Director | Wang Weidong | 350,000 | 36.36 | 75.05 | 350,000 | | Executive Director | He Ruyi | 24,200 | 36.36 | 75.05 | 24,200 | | Executive Director | Lin Jian | 14,850 | 36.36 | 75.05 | 14,850 | | Other Senior Management, Major Shareholders & Employees | Subtotal | 2,480,400 | 36.36 | 75.05 | 2,465,550 | - All A-share awards were granted on December 28, 2022, with a vesting period extending to December 27, 2028[3](index=3&type=chunk) [Other Information](index=3&type=section&id=Other%20Information) This section includes the announcement publication date and board composition as of that date, reaffirming that all other information and content of the 2022 annual report remain unchanged - This supplemental announcement was published on **September 11, 2023**[4](index=4&type=chunk) - As of the announcement date, the board of directors comprises **4 executive directors, 2 non-executive directors, and 3 independent non-executive directors**[4](index=4&type=chunk) - Except for the supplementary information disclosed in this announcement, all other information and content of the 2022 annual report remain unchanged[3](index=3&type=chunk)

Financial Performance - For the six months ended June 30, 2023, the company reported revenue of RMB 419,073 thousand, an increase from RMB 348,779 thousand in the same period of 2022, representing a growth of approximately 20.1%[2] - The gross profit for the same period was RMB 316,418 thousand, compared to RMB 181,274 thousand in 2022, indicating a significant increase of approximately 74.5%[2] - The company reported a loss before tax of RMB 703,362 thousand for the six months ended June 30, 2023, compared to a loss of RMB 489,126 thousand in the prior year, representing an increase in loss of approximately 43.8%[2] - The basic loss per share for the period was RMB 1.30, compared to RMB 0.96 in the same period of 2022, indicating a deterioration in earnings per share[2] - There were no income tax expenses reported for the periods in question, consistent with prior reporting[2] Research and Development - Research and development costs rose to RMB 540,453 thousand, up from RMB 449,672 thousand in 2022, reflecting an increase of about 20.2%[2] - The company continues to focus on expanding its research and development efforts, as indicated by the significant increase in R&D expenditure[2] Reporting and Compliance - The company clarified that the financial results are unaudited and should be read in conjunction with the full interim report for the six months ended June 30, 2023[3] - The announcement serves as a correction to the previous interim results announcement dated August 21, 2023, ensuring accuracy in the reported figures[1] - The company advises shareholders to refer to the full interim report for comprehensive details on financial performance and strategic direction[3]

R&D Investment and Development - The company is committed to maintaining a significant scale of R&D investment for ongoing product clinical trials and new drug market preparations[4]. - The total R&D investment amounted to ¥540,452,903.93, representing a 20.19% increase compared to ¥449,671,836.54 in the same period last year[53]. - Research and development expenses amounted to 540 million RMB, reflecting a growth of 20.19% year-over-year, indicating a continued commitment to expanding the R&D pipeline[66]. - The research and development expenditure accounted for 127.94% of operating revenue, slightly down from 128.34% in the previous year[24]. - The increase in R&D expenses is attributed to the expansion of the new drug pipeline and the advancement of multiple innovative drugs into critical trial phases[55]. - The company has established three core technology platforms with independent intellectual property rights, including antibody and fusion protein platform, ADC platform, and bifunctional antibody platform[49]. - The company has developed candidate drugs for tumor treatment based on its bifunctional antibody platform, which have shown significant biological activity in preclinical studies[49]. - The company has a comprehensive integrated ADC platform, making it one of the few biopharmaceutical companies in China with such capabilities[49]. - The company has established various original technologies for screening monoclonal antibodies with drug-like potential, including hybridoma monoclonal antibody platform and human antibody library phage display platform[49]. - The company is focused on innovative therapeutic antibody drugs, including antibody-drug conjugates (ADC) and bispecific antibodies, aiming to address unmet clinical needs in autoimmune diseases, oncology, and ophthalmology[29]. Financial Performance - The company reported a significant increase in the objective response rate (ORR) for its leading oncology product, indicating improved efficacy in patient outcomes[14]. - The company's operating revenue for the first half of 2023 was ¥422,427,546.05, representing a year-on-year increase of 20.56% compared to ¥350,374,980.22 in the same period last year[23]. - The net profit attributable to shareholders of the listed company was -¥703,360,797.19, a decrease from -¥489,125,226.86 in the previous year, indicating ongoing losses despite increased sales[23]. - The net assets attributable to shareholders decreased by 13.76% to ¥4,295,151,715.61 from ¥4,980,299,629.44 at the end of the previous year[23]. - The total assets decreased by 3.16% to ¥5,831,113,332.45 from ¥6,021,189,680.87 at the end of the previous year[23]. - Basic earnings per share for the first half of 2023 were -¥1.30, compared to -¥0.96 in the same period last year[24]. - The company reported a net cash flow from operating activities of -¥707,725,149.63, which is a slight increase in losses compared to -¥698,888,452.45 in the previous year[23]. - The weighted average return on net assets was -15.10%, a decrease of 4.06 percentage points from -11.04% in the previous year[24]. - The increase in sales revenue was attributed to higher sales of injectable drugs, specifically TaiTasi and VidiXimab, despite ongoing high costs for commercialization and R&D[25]. Clinical Trials and Product Development - The company is actively involved in clinical trial management through Site Management Organizations (SMOs) to enhance trial quality and compliance with regulations[13]. - The company is leveraging Contract Development and Manufacturing Organizations (CDMOs) for innovative drug process development and small-scale production[13]. - The company has achieved breakthrough therapy designation for new drugs that show substantial improvement in clinical endpoints during early trials, allowing access to expedited development and review[13]. - The company received orphan drug designation for treatments targeting diseases affecting fewer than 200,000 patients in the U.S., which grants a 7-year exclusivity period post-FDA approval[13]. - The company is committed to advancing its pipeline with a focus on diseases like systemic lupus erythematosus (SLE) and multiple sclerosis (MS), which are critical areas of unmet medical need[14]. - The company is exploring new market opportunities through strategic partnerships and potential acquisitions to expand its product offerings and market reach[14]. - The company has completed the first patient enrollment in several ongoing clinical trials, indicating progress in its research and development pipeline[31]. - The company has received breakthrough therapy designation for Tai'aisip in treating myasthenia gravis (MG) and is conducting a Phase III trial in China[32]. - The company has also initiated a Phase III clinical trial for Tai'aisip in treating primary Sjögren's syndrome (pSS) in China, with promising results from a previous Phase II trial published in a reputable journal[32]. - The company is conducting a Phase III clinical trial for Taitasip in treating NMOSD, which started in September 2017, with patient recruitment ongoing[34]. Market and Strategic Initiatives - The company is exploring Taitasip for other autoimmune diseases, with numerous investigator-initiated studies underway[35]. - The company is considering strategic acquisitions to bolster its market position, with a budget of up to 500 million earmarked for potential targets[125]. - The company is planning to expand its market presence in Southeast Asia, targeting a 15% market share by the end of 2024[149]. - The company is investing heavily in R&D, with a budget allocation of 200 million for new technologies aimed at enhancing user experience and operational efficiency[153]. - The company is implementing new strategies to enhance its research and development capabilities, aiming for faster time-to-market for innovative therapies[14]. - The company is actively recruiting talent across R&D, management, sales, and production to support its business growth and product pipeline expansion[71]. Environmental and Regulatory Compliance - The company has established an environmental protection mechanism and is classified as a key pollutant discharge unit[102]. - The company reported a total wastewater discharge of 88,343 tons for the year 2022, with ammonia nitrogen concentration at 15.7 mg/L, well below the limit of 45 mg/L[104]. - The chemical oxygen demand (COD) in wastewater was recorded at 146 mg/L, significantly lower than the permissible limit of 500 mg/L, with a total COD discharge of 14.475 tons[104]. - The company has implemented a self-monitoring plan for environmental compliance, with all monitored pollutants meeting discharge standards[109]. - The company has not reported any administrative penalties related to environmental issues during the reporting period[110]. - The company has not taken specific measures to reduce carbon emissions during the reporting period[112]. Shareholder and Governance Commitments - The company commits to not reducing its holdings of A shares before achieving profitability for three complete fiscal years post-listing[120]. - The company will comply with relevant laws and regulations regarding share lock-up and reduction, ensuring that any share reduction does not occur below the issue price within two years post-lock-up[120]. - The company has established a commitment to not transfer or manage shares for 12 months post-listing or for six months after leaving the company[121]. - The company will report any changes in shareholdings during the tenure of directors and senior management, with a maximum transfer limit of 25% of their holdings per year[120]. - The company will adhere to the Shanghai Stock Exchange regulations regarding share reduction and lock-up periods[120]. - The company has established a three-year shareholder dividend return plan post-IPO, focusing on stable returns based on profitability and business development[138]. - The company emphasizes the importance of governance structure improvement to enhance operational efficiency[137]. - The company will strictly adhere to its profit distribution policy as outlined in its articles of association and the prospectus post-IPO[140]. - The company has committed to timely disclosure of any failure to fulfill its commitments and will seek to protect investor rights through supplementary commitments[140]. - The company will not distribute dividends or compensation to its executives if commitments are not fulfilled[144].

Financial Performance - The company's product sales and R&D service revenue for the six months ended June 30, 2023, was approximately RMB 419.1 million, a 20% increase compared to RMB 348.8 million in the same period last year, driven by strong sales of its immunotherapy product Tai Aisi (RC18) and anti-tumor product Ai Di Xi (RC48) [2] - As of June 30, 2023, the group reported revenue of approximately RMB 419.1 million and gross profit of approximately RMB 316.4 million [5] - The company's revenue increased from RMB 348.8 million for the six months ended June 30, 2022, to RMB 419.1 million for the six months ended June 30, 2023, driven by strong sales of the self-immune product Taitasip and the anti-tumor product Vidisitimab [39] - The gross profit for the same period was RMB 316,418 thousand, compared to RMB 181,274 thousand in 2022, indicating a significant increase in profitability [61] - The company reported a loss before tax of RMB 703,362 thousand for the six months ended June 30, 2023, compared to a loss of RMB 489,126 thousand in the same period of 2022 [61] - The company's loss for the period rose from RMB 489.1 million to RMB 703.4 million [50] Research and Development - In January 2023, the FDA approved Tai Aisi (RC18) for the treatment of generalized myasthenia gravis (gMG) and granted it Fast Track designation [3] - In February 2023, the company received approval for the clinical trial application of Ai Di Xi (RC48) in combination with Ma Lai Suan Pi Luo Ti Ni tablets for patients with HER2 gene mutations [3] - The company is expanding its product pipeline with multiple new drug clinical trial applications approved in 2023, indicating a strong focus on R&D and market expansion [4] - The company has established a comprehensive end-to-end drug development capability, with seven candidate drugs currently in clinical development [7] - The company is conducting late-stage clinical trials for its proprietary fusion protein, Tai Tasi Pi (RC18), targeting eight autoimmune diseases [10] - The company is exploring the potential of Taitasib for other indications, including IgG4-related diseases and antiphospholipid syndrome, while continuing to seek global approval pathways for autoimmune diseases [19] Clinical Trials and Approvals - The company initiated a Phase III clinical trial for RC28-E, an injection for the treatment of wet age-related macular degeneration (wAMD), in January 2023 [4] - In April 2023, the NMPA approved Ai Di Xi (RC48) for a clinical trial in combination with radiotherapy for patients with HER2-expressing locally advanced solid tumors [4] - The NMPA approved the company's product RC48 for a Phase II clinical study in July 2023, targeting recurrent or metastatic cervical cancer patients [5] - The company received NMPA approval for its first bispecific antibody product RC148 for solid tumor patients in July 2023 [5] - The company has achieved agreement with the CDE on the Phase III clinical trial protocol for Taitasib in treating pSS in August 2022, indicating regulatory progress [15] Financial Expenses and Losses - Total expenses for the six months ended June 30, 2023, were approximately RMB 1,059.2 million, with R&D expenses accounting for approximately RMB 540.5 million, an increase of about RMB 90.8 million or approximately 20.2% [6] - Adjusted net loss increased by approximately RMB 182.2 million or about 38.2% to approximately RMB 659.7 million [6] - Sales and distribution expenses surged from RMB 150.0 million to RMB 350.2 million, primarily due to the expansion of the sales scale and increased marketing expenses [41] - Administrative expenses increased from RMB 106.9 million to RMB 168.6 million, mainly due to higher employee costs and depreciation from new facilities [43] - The total employee compensation cost for the six months ended June 30, 2023, was approximately RMB 571.7 million, an increase from RMB 335.3 million in the same period of 2022, primarily due to an increase in employee numbers and salary levels [56] Market Strategy and Expansion - The company aims to expand its market presence in China and internationally, focusing on clinical trials for Taitasip and Vidisitimab [38] - The company is expanding its marketing strategy to interact directly with key opinion leaders and physicians to promote its products effectively [36] - The company has established independent sales teams for autoimmune and oncology products, with over 600 hospitals approved for the sales of its products as of June 30, 2023 [36] Assets and Liabilities - As of June 30, 2023, the company's cash and cash equivalents decreased to RMB 1,119.7 million from RMB 2,069.2 million as of December 31, 2022, primarily due to increased operating and investment expenditures [51] - The company's debt, including bank loans and other borrowings, amounted to RMB 542.8 million as of June 30, 2023, with a debt-to-asset ratio of 26.3%, up from 17.3% as of December 31, 2022 [52] - Total liabilities increased to RMB 1,535,961 thousand from RMB 1,040,891 thousand, reflecting a rise of 47.5% [64] - The company's total equity decreased to RMB 4,295,152 thousand from RMB 4,980,300 thousand, a decline of 13.8% [64] Corporate Governance and Compliance - The company is subject to regulatory oversight from the National Medical Products Administration (NMPA) in China [92] - The company’s governance adheres to the corporate governance code as per the listing rules [90] - The company is listed on both the Hong Kong Stock Exchange (H shares) and the Shanghai Stock Exchange (A shares) [90]

| 证券代码：688331 | 证券简称：荣昌生物 | 公告编号： | 2023-023 | | --- | --- | --- | --- | | 港股代码：09995 | 港股简称：榮昌生物 | | | 荣昌生物制药（烟台）股份有限公司 2023年半年度募集资金存放与实际使用情况的专项报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 根据中国证券监督管理委员会发布的《上市公司监管指引第 2 号——上市公 司募集资金管理和使用的监管要求》和上海证券交易所颁布的《上海证券交易所 科创板上市公司自律监管指引第 1 号——规范运作》等的相关规定，荣昌生物制 药（烟台）股份有限公司（以下简称"公司"）将 2023 年上半年募集资金存放 与使用情况专项报告如下： 一、募集资金基本情况 （一）实际募集资金金额及资金到账情况 经中国证券监督管理委员会《关于同意荣昌生物制药（烟台）股份有限公司 首次公开发行股票注册的批复》（证监许可[2022]62 号）核准，公司首次公开 发行人民币普通股（A 股）股票 5,442.6301 万股， ...

荣昌生物制药（烟台）股份有限公司 第二届监事会第二次会议决议公告 | 证券代码：688331 | 证券简称：荣昌生物 | 公告编号： | 2023-022 | | --- | --- | --- | --- | | 港股代码：09995 | 港股简称：榮昌生物 | | | 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 准确、完整，所载资料不存在任何虚假记载、误导性陈述或者重大遗漏。 一、监事会会议召开情况 荣昌生物制药（烟台）股份有限公司（以下简称"公司"）第二届监事会第二 次会议，于 2023 年 8 月 21 日在公司会议室以现场方式召开，会议已于 2023 年 8 月 7 日以邮件方式发出会议通知。会议应出席监事 3 名，实际出席监事 3 名， 会议由任广科先生主持，会议的召集、召开、表决程序符合《中华人民共和国公 司法》和《荣昌生物制药（烟台）股份有限公司章程》（以下简称"公司章程"） 的相关规定，所作决议合法有效。经与会监事表决，会议形成如下决议： 二、监事会会议审议情况 1、审议通过《关于公司 2023 年半年度 ...

Financial Performance - The company's operating revenue for Q1 2023 was ¥168,238,991.99, representing a year-on-year increase of 12.06%[4] - The net profit attributable to shareholders was -¥323,774,631.80, and the net profit after deducting non-recurring gains and losses was -¥331,792,406.63[4] - The company reported a net loss of CNY 322,166,168.74 for Q1 2023, compared to a loss of CNY 282,670,647.07 in Q1 2022, indicating a worsening of about 14.0%[16] - Total comprehensive income for Q1 2023 was -326,630,103.58 RMB, compared to -287,615,486.11 RMB in Q1 2022, reflecting a decline of about 13.6% year-over-year[17] - Basic and diluted earnings per share were both -¥0.60[5] - Basic and diluted earnings per share for Q1 2023 were both -0.60 RMB, slightly worse than -0.59 RMB in Q1 2022[17] Cash Flow - The net cash flow from operating activities was -¥349,845,397.38[4] - Cash inflows from operating activities totaled 224,413,979.30 RMB in Q1 2023, up from 115,680,554.56 RMB in Q1 2022, representing an increase of approximately 93.9%[19] - Cash outflows from operating activities amounted to 574,259,376.68 RMB in Q1 2023, compared to 466,158,621.88 RMB in Q1 2022, an increase of about 23.2%[19] - The net cash flow from operating activities was -349,845,397.38 RMB in Q1 2023, slightly improved from -350,478,067.32 RMB in Q1 2022[19] - Cash and cash equivalents decreased to CNY 1,250,643,639.07 as of March 31, 2023, down from CNY 2,187,326,306.04 at the end of 2022, a decline of approximately 42.7%[14] - Cash and cash equivalents at the end of Q1 2023 were 1,086,332,437.19 RMB, down from 3,735,640,216.30 RMB at the end of Q1 2022, a decrease of approximately 70.1%[19] - The company reported cash inflows from investment activities of 68,289,252.05 RMB in Q1 2023, with cash outflows totaling 652,378,663.59 RMB, resulting in a net cash flow from investment activities of -584,089,411.54 RMB[19] - The company did not report any cash inflows from financing activities in Q1 2023, contrasting with significant inflows of -2,612,462,448.00 RMB in the same period of the previous year[19] Assets and Liabilities - The total assets at the end of the reporting period were ¥5,678,394,849.53, a decrease of 5.69% compared to the end of the previous year[5] - Total assets as of March 31, 2023, were CNY 5,678,394,849.53, down from CNY 6,021,189,680.87 at the end of 2022, representing a decrease of about 5.7%[15] - The total liabilities decreased to CNY 997,690,914.23 as of March 31, 2023, from CNY 1,040,890,051.43 at the end of 2022, a reduction of approximately 4.1%[15] - The equity attributable to shareholders decreased by 6.02% to ¥4,680,703,935.30 compared to the end of the previous year[5] - The company’s total equity attributable to shareholders was CNY 4,680,703,935.30 as of March 31, 2023, down from CNY 4,980,299,629.44 at the end of 2022, a decrease of about 6.0%[15] Research and Development - Research and development expenses totaled ¥249,722,218.25, accounting for 148.43% of operating revenue, an increase of 3.11 percentage points year-on-year[5] - Research and development expenses for Q1 2023 were CNY 249,722,218.25, up from CNY 218,173,558.62 in Q1 2022, reflecting a rise of approximately 14.5%[16] - The company plans to continue focusing on R&D and market expansion strategies to improve future performance[16] Shareholder Information - The company had a total of 8,017,774.83 shares outstanding at the end of the reporting period[7] - The top shareholder, HKSCC NOMINEES LIMITED, held 34.83% of the shares, totaling 189,566,228 shares[8] - The number of common shareholders as of the reporting date was 5,654, with 5,628 A-share and 26 H-share shareholders[12] Accounting Practices - The company has not adopted new accounting standards for the year 2023, indicating continuity in financial reporting practices[20]